

Webinar: The Use and Development of DHTs with Patient Advocacy Groups



The image is a promotional graphic for a webinar. It features a dark blue background with a faint pattern of people and technical icons. In the top left, there are logos for 'RARE AND ORPHAN DISEASE PROGRAMS' and 'RDCA-DAP® Rare Disease Cures Accelerator Data and Analytics Platform'. The text 'WEBINAR SERIES' is prominently displayed in white. On the right, a yellow rounded rectangle contains the date and time 'Thurs | May 23 10 AM ET' and a large blue 'REGISTER NOW' button with a white cursor icon. In the center, a man in a light blue shirt stands with his arms crossed. To his right, the title 'The Use and Development of DHTs with Patient Advocacy Groups' is written in yellow. At the bottom, a blue bar contains the speaker's name and affiliations in white and yellow text.

RARE AND ORPHAN
DISEASE PROGRAMS
CRITICAL PATH INSTITUTE

RDCA-DAP®
Rare Disease Cures Accelerator
Data and Analytics Platform

WEBINAR SERIES

Thurs | May 23
10 AM ET

REGISTER
NOW

**The Use and
Development of
DHTs with Patient
Advocacy Groups**

Laurent Servais, MD, PhD
University of Oxford, UK,
University of Liège, Belgium

On Thursday, May 23, C-Path was joined by Dr. [Laurent Servais](#) of the University of Oxford and the University of Liège, for an overview of Actimyo and relevant learnings from use cases across rare disorders spanning different degrees of complexity and readiness. Additionally, patient advocacy group leaders will speak to their experience based on stage of development and the ability of Actimyo to assess individuals with a neuromuscular disorder or non-NMDs (e.g., Duchenne muscular dystrophy, Angelman syndrome, and CTNNB1).

View the webinar recording below: